What is the difference between Mvasi and Avastin?
Medically reviewed by Drugs.com. Last updated on Sep 16, 2019.
A biosimilar, according to the FDA, is a biological product that is highly similar to an FDA-approved biological product, known as a reference product (in this case Avastin), and has no clinically meaningful differences in terms of safety and effectiveness.
Both Mvasi and Avastin are indicated for multiple types of cancer, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, brain cancer (glioblastoma), metastatic renal cell carcinoma (kidney cancer) and cervical cancers.
See also: Comparing Avastin vs Mvasi
Related Medical Questions
- How many biosimilars have been approved in the United States?
- What is the difference between Opdivo and Keytruda?
- What is Paxil called in the USA?
- Pembrolizumab vs. nivolumab: how do they compare?
- What is the cost of Tecentriq?
- How long do you take Alecensa for?
- How effective is Alecensa for ALK-positive NSCLC?
- How does Alecensa work?
- What is Tagrisso used for?
- What type of cancer is Tecentriq used to treat?
- What type of drug is Libtayo?
- What type of lung cancer is Vizimpro used to treat?
- What type of drug is Lorbrena?
- What is Alecensa used to treat?
- What type of drug is Alunbrig?
Related Support Groups
- Avastin (4 questions, 43 members)
- Bevacizumab (2 questions, 7 members)
- Mvasi (2 questions, 3 members)
- Non-Small Cell Lung Cancer (18 questions, 60 members)
- Renal Cell Carcinoma (11 questions, 93 members)
- Colorectal Cancer (7 questions, 50 members)
- Cervical Cancer (3 questions, 23 members)
- Glioblastoma Multiforme (1 questions, 26 members)